Innate Sheds 30% of Staff, Narrows Pipeline Focus Amid ‘Challenging Funding Environment’

Moving forward, Innate will focus on the clinical development of its antibody-drug conjugate IPH4502, the lymphoma candidate lacutamab and the AstraZeneca-partnered monalizumab.